| Bioactivity | Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis[1][2][3]. |
| In Vivo | Etanercept (10 mg/kg; s.c.; every 3 days for 3 weeks) significantly decreases the mean arthritis scores and radiological score[4]. Animal Model: |
| Name | Etanercept |
| CAS | 185243-69-0 |
| Molar Mass | 150 kDa(Average) |
| Appearance | Liquid |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Goffe B, et al. Etanercept: An overview. J Am Acad Dermatol. 2003;49(2 Suppl):S105-S111. [2]. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21(1):75-2. [3]. Haraoui B, et al. Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2007;3(1):99-105. [4]. Totoson P, et al. Etanercept improves endothelial function via pleiotropic effects in rat adjuvant-induced arthritis. Rheumatology (Oxford). 2016;55(7):1308-1317. |
Etanercept
CAS: 185243-69-0 F: W: 150 kDa(Average)
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the bind
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.